Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
24 Enero 2024 - 7:00AM
Rezolute, Inc. (Nasdaq: RZLT), a
clinical-stage biopharmaceutical company committed to
developing novel, transformative therapies for serious
metabolic and rare diseases, today announced the addition of Daron
Evans, MS, MBA, to its leadership team as Chief Financial Officer
as well as the grant of share options as a material inducement for
his appointment (the “Inducement Grant”).
About Mr. Evans
“This is a pivotal year for Rezolute as we
initiated our Phase 3 clinical study for RZ358 in congenital
hyperinsulinism and anticipate reporting topline data from our
Phase 2 study for RZ402 in diabetic macular edema in the second
quarter of 2024,” said Nevan Charles Elam, Chief Executive Officer
and Founder of Rezolute. “As a seasoned biotech leader and
entrepreneur, Mr. Evans has recognized the value of our novel
therapies for rare and metabolic disease. His experience in
corporate finance, capital markets, and strategic transactions will
help shepherd Rezolute through its next chapter in late-stage
development and support its mission to help patients in need.”
Mr. Evans has over 15 years of experience
leading public and private life science companies through financial
operations, investor relations, and business development
activities. Prior to joining Rezolute, he served as Chief Executive
Officer of AlloRock, Inc., a biotechnology company in the
cardiometabolic disease space, as well as Chief Executive Officer
of Specialty Renal Products, Inc., a medical device company in the
dialysis space. Previously, Mr. Evans served as Chief Executive
Officer of Nephros, Inc., and Chief Financial Officer of Nile
Therapeutics, Inc. Since 2015, Mr. Evans has been Managing Director
of PoC Capital, LLC, a fund focused on investing in public life
science companies. He holds a Bachelor of Science in Chemical
Engineering from Rice University, a Master of Science in Biomedical
Engineering from a joint program at the University of Texas at
Arlington and Southwestern Medical School, and a Master of Business
Administration from the Fuqua School of Business at Duke
University.
“Rezolute is on the precipice of potentially
making a significant impact on the lives of patients and their
families in multiple indications,” said Mr. Evans. “I am very
impressed with the dedication and experience of the Rezolute team
and am honored to join the mission at this critical time.”
Inducement Grant
In connection with Mr. Evans’ appointment, on
January 23, 2024, the Company’s Board of Directors, upon
recommendation of the Compensation Committee, approved the grant of
an inducement stock option of 275,000 shares of the Company’s
common stock in accordance with Nasdaq Listing Rule 5635(c)(4). The
option has an exercise price of $1.02 per share, which is equal to
the closing price of Rezolute’s common stock on January 23, 2024.
The stock options will vest and become exercisable as to 25% of the
underlying shares on the first anniversary of the grant date, and
will vest and become exercisable as to the remaining 75% of the
underlying shares in 36 equal monthly installments from the first
anniversary of the grant date, subject to his continued employment
with Rezolute on such vesting dates. If the Company is acquired
during his employment, all remaining options will automatically
vest.
About Rezolute, Inc.Rezolute
strives to disrupt current treatment paradigms by developing
transformative therapies for devastating rare and chronic metabolic
diseases. Its novel therapies hold the potential to both
significantly improve outcomes and reduce the treatment burden for
patients, treating physicians, and the healthcare system. Rezolute
is steadfast in its mission to create profound, positive, and
lasting impacts on patients’ lives. Patient, clinician, and
advocate voices are integrated in the Company’s drug development
process. Rezolute places an emphasis on understanding the patient’s
lived experiences, enabling the Company to boldly address a range
of severe conditions. For more information,
visit www.rezolutebio.com.
Forward-Looking Statements
This release, like many written and oral
communications presented by Rezolute and our authorized officers,
may contain certain forward-looking statements regarding our
prospective performance and strategies within the meaning of
Section 27A of the Securities Act and Section 21E of the Securities
Exchange Act of 1934, as amended. We intend such forward-looking
statements to be covered by the safe harbor provisions for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995 and are including this statement for
purposes of said safe harbor provisions. Forward-looking
statements, which are based on certain assumptions and describe
future plans, strategies, and expectations of Rezolute, are
generally identified by use of words such as "anticipate,"
"believe," "estimate," "expect," "intend," "plan," "project,"
"seek," "strive," "try," or future or conditional verbs such as
"could," "may," "should," "will," "would," or similar expressions.
These forward-looking statements include, but are
not limited to statements regarding the appointment of Daron Evans
as Chief Financial Officer, the Inducement Grant for Daron Evans’
appointment, the Innovation Passport designation, the PRIME
designation and the meaning of the designations on the ability of
RZ358 to become an effective treatment for congenital
hyperinsulinism, the effectiveness or future effectiveness of RZ358
for the treatment of congenital hyperinsulinism, and statements
regarding clinical trial timelines for RZ358. Our ability to
predict results or the actual effects of our plans or strategies is
inherently uncertain. Accordingly, actual results may differ
materially from anticipated results. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date of this release. Except as required by
applicable law or regulation, Rezolute undertakes no obligation to
update these forward-looking statements to reflect events or
circumstances that occur after the date on which such statements
were made. Important factors that may cause such a difference
include any other factors discussed in our filings with the SEC,
including the Risk Factors contained in the Rezolute’s Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q, which are
available at the SEC’s website at www.sec.gov. You are urged to
consider these factors carefully in evaluating the forward-looking
statements in this release and are cautioned not to place undue
reliance on such forward-looking statements, which are qualified in
their entirety by this cautionary statement.
Investors & Media:Christen
BaglaneasRezolute, Inc.cbaglaneas@rezolutebio.com (508)
272-6717
Investors:Stephanie CarringtonICR
WestwickeRezoluteIR@westwicke.com (646) 277-1282
Rezolute (NASDAQ:RZLT)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Rezolute (NASDAQ:RZLT)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024